File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Epitope specificity of antibodies to type II collagen in rheumatoid arthritis and systemic lupus erythematosus
  • Basic View
  • Metadata View
  • XML View
TitleEpitope specificity of antibodies to type II collagen in rheumatoid arthritis and systemic lupus erythematosus
 
AuthorsRowley, MJ1
Mackay, IR1
Brand, CA1
Bateman, JF1
Chan, D1
 
Issue Date1992
 
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00296/index.htm
 
CitationRheumatology International, 1992, v. 12 n. 2, p. 65-69 [How to Cite?]
DOI: http://dx.doi.org/10.1007/BF00300979
 
AbstractAntibodies to human type II collagen were examined in the sera of 105 patients with rheumatoid arthritis (RA), 44 patients with systemic lupus erythematosus (SEF) and 11 patients who fulfilled the criteria of both diseases (RA-SLE overlap), using a solid-phase radioimmunoassay (RIA). The frequencies of antibodies to native and denatured human type II collagen were 20% and 27% in RA, 14% and 16% in SLE, and 45% and 36% in RA-SLE overlap. The specificity of the antibodies was further examined by inhibition with native and denatured type II collagen, by immunoblotting on native and denatured type II collagen, and by immunoblotting on cyanogen-bromide derived polypeptides of type II collagen. We could not identify any disease-specific patterns of reactivity. Thus, in the three disease groups the antibody response was polyclonal; there were antibody populations that reacted with native and/or denatured collagen, and epitopes could be assigned to at least three CB peptides, CB10.5, CB11 and CB8.
 
ISSN0172-8172
2012 Impact Factor: 2.214
2012 SCImago Journal Rankings: 0.580
 
DOIhttp://dx.doi.org/10.1007/BF00300979
 
ISI Accession Number IDWOS:A1992JA83300005
 
DC FieldValue
dc.contributor.authorRowley, MJ
 
dc.contributor.authorMackay, IR
 
dc.contributor.authorBrand, CA
 
dc.contributor.authorBateman, JF
 
dc.contributor.authorChan, D
 
dc.date.accessioned2012-05-29T06:03:14Z
 
dc.date.available2012-05-29T06:03:14Z
 
dc.date.issued1992
 
dc.description.abstractAntibodies to human type II collagen were examined in the sera of 105 patients with rheumatoid arthritis (RA), 44 patients with systemic lupus erythematosus (SEF) and 11 patients who fulfilled the criteria of both diseases (RA-SLE overlap), using a solid-phase radioimmunoassay (RIA). The frequencies of antibodies to native and denatured human type II collagen were 20% and 27% in RA, 14% and 16% in SLE, and 45% and 36% in RA-SLE overlap. The specificity of the antibodies was further examined by inhibition with native and denatured type II collagen, by immunoblotting on native and denatured type II collagen, and by immunoblotting on cyanogen-bromide derived polypeptides of type II collagen. We could not identify any disease-specific patterns of reactivity. Thus, in the three disease groups the antibody response was polyclonal; there were antibody populations that reacted with native and/or denatured collagen, and epitopes could be assigned to at least three CB peptides, CB10.5, CB11 and CB8.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationRheumatology International, 1992, v. 12 n. 2, p. 65-69 [How to Cite?]
DOI: http://dx.doi.org/10.1007/BF00300979
 
dc.identifier.doihttp://dx.doi.org/10.1007/BF00300979
 
dc.identifier.epage69
 
dc.identifier.isiWOS:A1992JA83300005
 
dc.identifier.issn0172-8172
2012 Impact Factor: 2.214
2012 SCImago Journal Rankings: 0.580
 
dc.identifier.issue2
 
dc.identifier.pmid1384102
 
dc.identifier.scopuseid_2-s2.0-0026659023
 
dc.identifier.spage65
 
dc.identifier.urihttp://hdl.handle.net/10722/147370
 
dc.identifier.volume12
 
dc.languageeng
 
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00296/index.htm
 
dc.publisher.placeGermany
 
dc.relation.ispartofRheumatology International
 
dc.subject.meshAntibodies - Analysis - Immunology
 
dc.subject.meshAntibody Specificity
 
dc.subject.meshArthritis, Rheumatoid - Blood - Diagnosis - Immunology
 
dc.subject.meshBiological Markers - Blood
 
dc.subject.meshCollagen - Immunology
 
dc.subject.meshEpitopes - Immunology
 
dc.subject.meshHumans
 
dc.subject.meshImmunoblotting
 
dc.subject.meshLupus Erythematosus, Systemic - Blood - Diagnosis - Immunology
 
dc.subject.meshRadioimmunoassay
 
dc.titleEpitope specificity of antibodies to type II collagen in rheumatoid arthritis and systemic lupus erythematosus
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Rowley, MJ</contributor.author>
<contributor.author>Mackay, IR</contributor.author>
<contributor.author>Brand, CA</contributor.author>
<contributor.author>Bateman, JF</contributor.author>
<contributor.author>Chan, D</contributor.author>
<date.accessioned>2012-05-29T06:03:14Z</date.accessioned>
<date.available>2012-05-29T06:03:14Z</date.available>
<date.issued>1992</date.issued>
<identifier.citation>Rheumatology International, 1992, v. 12 n. 2, p. 65-69</identifier.citation>
<identifier.issn>0172-8172</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/147370</identifier.uri>
<description.abstract>Antibodies to human type II collagen were examined in the sera of 105 patients with rheumatoid arthritis (RA), 44 patients with systemic lupus erythematosus (SEF) and 11 patients who fulfilled the criteria of both diseases (RA-SLE overlap), using a solid-phase radioimmunoassay (RIA). The frequencies of antibodies to native and denatured human type II collagen were 20% and 27% in RA, 14% and 16% in SLE, and 45% and 36% in RA-SLE overlap. The specificity of the antibodies was further examined by inhibition with native and denatured type II collagen, by immunoblotting on native and denatured type II collagen, and by immunoblotting on cyanogen-bromide derived polypeptides of type II collagen. We could not identify any disease-specific patterns of reactivity. Thus, in the three disease groups the antibody response was polyclonal; there were antibody populations that reacted with native and/or denatured collagen, and epitopes could be assigned to at least three CB peptides, CB10.5, CB11 and CB8.</description.abstract>
<language>eng</language>
<publisher>Springer Verlag. The Journal&apos;s web site is located at http://link.springer.de/link/service/journals/00296/index.htm</publisher>
<relation.ispartof>Rheumatology International</relation.ispartof>
<subject.mesh>Antibodies - Analysis - Immunology</subject.mesh>
<subject.mesh>Antibody Specificity</subject.mesh>
<subject.mesh>Arthritis, Rheumatoid - Blood - Diagnosis - Immunology</subject.mesh>
<subject.mesh>Biological Markers - Blood</subject.mesh>
<subject.mesh>Collagen - Immunology</subject.mesh>
<subject.mesh>Epitopes - Immunology</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Immunoblotting</subject.mesh>
<subject.mesh>Lupus Erythematosus, Systemic - Blood - Diagnosis - Immunology</subject.mesh>
<subject.mesh>Radioimmunoassay</subject.mesh>
<title>Epitope specificity of antibodies to type II collagen in rheumatoid arthritis and systemic lupus erythematosus</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1007/BF00300979</identifier.doi>
<identifier.pmid>1384102</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0026659023</identifier.scopus>
<identifier.volume>12</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>65</identifier.spage>
<identifier.epage>69</identifier.epage>
<identifier.isi>WOS:A1992JA83300005</identifier.isi>
<publisher.place>Germany</publisher.place>
</item>
Author Affiliations
  1. Monash University